| __timestamp | Apellis Pharmaceuticals, Inc. | Vertex Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 8379522 | 855506000 |
| Thursday, January 1, 2015 | 13730311 | 996170000 |
| Friday, January 1, 2016 | 22978599 | 1047690000 |
| Sunday, January 1, 2017 | 40303878 | 1324625000 |
| Monday, January 1, 2018 | 105285576 | 1416476000 |
| Tuesday, January 1, 2019 | 220968770 | 1754540000 |
| Wednesday, January 1, 2020 | 299921000 | 1829537000 |
| Friday, January 1, 2021 | 420869000 | 3051100000 |
| Saturday, January 1, 2022 | 387236000 | 2540300000 |
| Sunday, January 1, 2023 | 354387000 | 3162900000 |
| Monday, January 1, 2024 | 3630300000 |
Unleashing insights
In the competitive world of pharmaceuticals, innovation is key. Over the past decade, Vertex Pharmaceuticals Incorporated has consistently outpaced Apellis Pharmaceuticals, Inc. in research and development (R&D) spending. From 2014 to 2023, Vertex's R&D expenses grew by an impressive 270%, peaking at over $3.16 billion in 2023. In contrast, Apellis saw a significant increase of 4,130% in the same period, yet their R&D spending reached only $420 million at its highest in 2021.
Vertex's commitment to innovation is evident, with R&D expenses averaging nearly $1.8 billion annually, compared to Apellis's $187 million. This substantial investment has positioned Vertex as a leader in the industry, driving advancements in treatments and therapies. As the pharmaceutical landscape evolves, the disparity in R&D spending highlights the strategic priorities of these two companies, with Vertex clearly prioritizing innovation at a larger scale.
Analyzing R&D Budgets: Merck & Co., Inc. vs Apellis Pharmaceuticals, Inc.
Research and Development Investment: Vertex Pharmaceuticals Incorporated vs Regeneron Pharmaceuticals, Inc.
R&D Insights: How Vertex Pharmaceuticals Incorporated and Viatris Inc. Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for Vertex Pharmaceuticals Incorporated and Exelixis, Inc.
Research and Development Expenses Breakdown: Vertex Pharmaceuticals Incorporated vs Viking Therapeutics, Inc.
Vertex Pharmaceuticals Incorporated vs Catalyst Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Vertex Pharmaceuticals Incorporated vs Ligand Pharmaceuticals Incorporated: Strategic Focus on R&D Spending
R&D Spending Showdown: Intra-Cellular Therapies, Inc. vs Apellis Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Madrigal Pharmaceuticals, Inc. and Apellis Pharmaceuticals, Inc.
R&D Spending Showdown: Apellis Pharmaceuticals, Inc. vs Arrowhead Pharmaceuticals, Inc.
Research and Development Investment: Apellis Pharmaceuticals, Inc. vs Celldex Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Apellis Pharmaceuticals, Inc. and Xencor, Inc.